Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 2/3 1

Status

Unknown 8Recruiting 7Completed 7Not yet recruiting 6Terminated 5Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 6Colorectal Neoplasms 2Unresectable Locally Advanced or Metastatic Solid Tumors 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastrointestinal Stromal Tumors 1Disease Progression 1Cirrhosis, Familial, with Pulmonary Hypertension 1Cholangiocarcinoma 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 10tislelizumab 9apatinib 9regorafenib 6camrelizumab 6donafenib 5atezolizumab 5Immune Checkpoint Inhibitors 4Hepatectomy 4cabozantinib 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2durvalumab 2anlotinib 2Surgical Procedures, Operative 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × regorafenib × Clear all
NCT07495579 2026-05-27

REVIVE

Asan Medical Center

Phase 2 Not yet recruiting
146 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07514429 2026-04-07

RELEVANT-HCC

Asan Medical Center

Phase 2 Not yet recruiting
24 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07514455 2026-04-07

RECOMEND

Asan Medical Center

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Disease Progression

NCT07392866 2026-02-09

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2/3 Not yet recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07115550 2025-08-11

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

Huai'an First People's Hospital

Phase NA Not yet recruiting
24 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07078305 2025-07-22

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
134 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡